Related Experiment Video

Updated: May 14, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

Annapaola Prestia1, Anna Caroli, Wiesje M van der Flier

  • 1LENITEM-Laboratory of Epidemiology Neuroimaging and Telemedicine, IRCCS Centro San Giovanni di Dio FBF, Brescia, Italy.

Neurology
|February 8, 2013
PubMed
Abstract

Insights

This study validates the Alzheimer disease (AD) biomarker model in mild cognitive impairment (MCI) patients. Findings show a clear link between biomarker abnormality progression and dementia development, supporting the current AD pathophysiologic model.

Area of Science:

  • Neurology
  • Biomarker Research
  • Neurodegenerative Diseases

Background:

  • The established Alzheimer disease (AD) model posits a specific biomarker sequence: amyloidosis, then hypometabolism, and finally atrophy.
  • Clinical validation of this model in early-stage neurodegeneration, such as mild cognitive impairment (MCI), is crucial for understanding disease progression.

Purpose of the Study:

  • To provide clinical evidence supporting the current Alzheimer disease pathophysiologic model in patients with mild cognitive impairment (MCI).
  • To assess the relationship between biomarker abnormality patterns and the progression to dementia in an MCI cohort.

Main Methods:

  • Included 73 MCI patients from European memory clinics.
  • Assessed brain amyloidosis (CSF Aβ42), cortical metabolism (FDG-PET temporoparietal hypometabolism index), and brain atrophy (hippocampal volume).
  • Categorized patients into groups based on biomarker positivity and analyzed dementia progression rates and timing.

Main Results:

  • Of 73 MCI patients, 29 progressed to dementia over follow-up.
  • Incident dementia rates increased significantly with greater biological severity (4% to 100%, p < 0.0001).
  • Progression to dementia occurred earlier in patients with more advanced biomarker abnormalities (p = 0.024).

Conclusions:

  • The observed biomarker patterns align with the current pathophysiologic model of Alzheimer disease.
  • A fully normal biomarker profile was associated with exceptional outcomes, while a fully abnormal profile predicted universal dementia development.
  • Deviations from the model may indicate atypical neurobiology or issues with biomarker abnormality thresholds.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...